Speakers: 

Kyle Retterer, MS is Geisinger's Chief Data Science Officer and oversees the Research Data Core.

Scott LeMaire, MD, FACS, FAHA is Geisinger's Associate Chief Scientific Officer and Associate Dean for Research. 

David Carey, PhD is a Professor in the Department of Genomic Health and serves as Geisinger's Research Integrity Officer. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Learn what data is available from MyCode and the process for incorporating it into your research.
2. Comprehend the differences between rare and common genetic variant effects and why they are important for study design.
3. Differentiate between genotype and phenotype-first analyses and when each is appropriate.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christa Martin, PhD, Eric Wright, PharmD, MPH, Adam Buchanan, MS, MPH, CGC, Candice Laubach, MBA, Jenn Nunamaker and Christian Lynch, MPH have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Speakers: Mr. Retterer has had a financial relationship within the past 24 months with Opko Health, Inc. (employee/stockholder). Dr. LeMaire has had a financial relationship within the past 24 months with Cerus (consultant/advisor) and CytoSorbents, Inc. (research grants), and Terumo Aortic (research grants). Dr. Carey has nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant. 

Commercial Support for this Session

None.